JoVE Logo
Faculty Resource Center

Sign In

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

DOI :

10.3791/57588-v

July 12th, 2018

July 12th, 2018

8,318 Views

1School of Pharmaceutical Sciences, Sun Yat-Sen University, 2Center for Cellular & Structural Biology, Sun Yat-Sen University

Here, we present a protocol to produce a bispecific antibody GPC3-S-Fab in Escherichia coli. The purified GPC3-S-Fab has potent cytotoxicity against GPC3 positive liver cancer cells.

Tags

GPC3 targeting Bispecific Antibody

-- Views

Related Videos

article

Labeling of Breast Cancer Patient-derived Xenografts with Traceable Reporters for Tumor Growth and Metastasis Studies

article

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

article

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

article

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity

article

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

article

An Automated Differential Nuclear Staining Assay for Accurate Determination of Mitocan Cytotoxicity

article

Monitoring Cancer Cell Invasion and T-Cell Cytotoxicity in 3D Culture

article

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo

article

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

article

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved